entertainment -WSS

entertainment

author：comprehensive 2025-09-07 04:09:31 - browse：9

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Inside the rise of 'mukbang' eating videos

explore

WSS

Mom launches Girl Scout troop for LGBTQ youth in Texas

'Reaching a detente': STAT's Helen Branswell on covering Covid

How to fix the rural physician shortage in the U.S.

Inside the rise of 'mukbang' eating videos

Stanford president to resign after investigation of research

Biogen nominates mother of director’s child to replace him on board

leisure time

entertainment

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Xenotransplantation trials will require adjusting expectations, experts say

As demand for Covid shots wanes, Moderna seeks its next success

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Psychedelics group wrestles with new pharma identity

Ebola public health emergency is over, WHO declares

Heart attack and stroke risk calculators need revising

Xenotransplantation trials will require adjusting expectations, experts say

Walensky prepares to leave CDC — and Congress — behind

Patients, doctors are clashing about side effects of hormonal birth control

knowledge

New warning issued for rebooking air travel after delays, cancellations

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Patients, doctors are clashing about side effects of hormonal birth control

Man who had jail sentence commuted by Trump arrested again

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

'Reaching a detente': STAT's Helen Branswell on covering Covid

entertainment

explore

focus

hotspot